Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.31+1.28 (+12.76%)
Close on Nov 17, 2026Market cap $224.25MP/E –Yield –
Keros Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Keros Therapeutics's total assets was $287.60M at Jun 30, 2026. For fiscal 2025 it was $338.02M, down 45.1% from the year before. The highest annual figure on record is $615.89M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $338.02M | -45.1% |
| FY2024 | Dec 31, 2024 | $615.89M | +66.4% |
| FY2023 | Dec 31, 2023 | $370.03M | +20.6% |
| FY2022 | Dec 31, 2022 | $306.78M | +20.2% |
| FY2021 | Dec 31, 2021 | $255.25M | -5.3% |
| FY2020 | Dec 31, 2020 | $269.44M | +2359.5% |
| FY2019 | Dec 31, 2019 | $10.96M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $287.60M | -62.0% |
| Q1 FY2026 | Mar 31, 2026 | $312.29M | -60.2% |
| Q4 FY2025 | Dec 31, 2025 | $338.02M | -45.1% |
| Q3 FY2025 | Sep 30, 2025 | $742.78M | +28.2% |
| Q2 FY2025 | Jun 30, 2025 | $757.17M | +66.4% |
| Q1 FY2025 | Mar 31, 2025 | $784.56M | +61.5% |
| Q4 FY2024 | Dec 31, 2024 | $615.89M | +66.4% |
| Q3 FY2024 | Sep 30, 2024 | $579.27M | +77.6% |
| Q2 FY2024 | Jun 30, 2024 | $455.02M | +27.7% |
| Q1 FY2024 | Mar 31, 2024 | $485.82M | +26.4% |
| Q4 FY2023 | Dec 31, 2023 | $370.03M | +20.6% |
| Q3 FY2023 | Sep 30, 2023 | $326.25M | +29.2% |
| Q2 FY2023 | Jun 30, 2023 | $356.31M | +57.2% |
| Q1 FY2023 | Mar 31, 2023 | $384.44M | +63.5% |
| Q4 FY2022 | Dec 31, 2022 | $306.78M | +20.2% |
| Q3 FY2022 | Sep 30, 2022 | $252.55M | +9.8% |
| Q2 FY2022 | Jun 30, 2022 | $226.66M | -6.9% |
| Q1 FY2022 | Mar 31, 2022 | $235.14M | -8.8% |
| Q4 FY2021 | Dec 31, 2021 | $255.25M | -5.3% |
| Q3 FY2021 | Sep 30, 2021 | $229.96M | +66.3% |
| Q2 FY2021 | Jun 30, 2021 | $243.46M | +61.8% |
| Q1 FY2021 | Mar 31, 2021 | $257.73M | +325.4% |
| Q4 FY2020 | Dec 31, 2020 | $269.44M | +2359.5% |
| Q3 FY2020 | Sep 30, 2020 | $138.25M | – |
| Q2 FY2020 | Jun 30, 2020 | $150.44M | – |
| Q1 FY2020 | Mar 31, 2020 | $60.59M | – |
| Q4 FY2019 | Dec 31, 2019 | $10.96M | – |
See a number that looks wrong?